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Abstract 
Context: We investigated the role of 68Ga-DOTATOC PET/CT in detecting somatostatin receptors 
(SSTRs) in 19 patients with metastatic adrenocortical carcinoma (ACC) and explored the activity of 
90Y/177Lu-DOTATOC Peptide Receptor Radionuclide Therapy (PRRT). 
Case description and methods. 68Ga uptake in metastatic sites was scored in terms of intensity 
and anatomical uptake distribution of standard uptake value (SUV). Tissue expression of SSTR2A 
and SSTR5 was also evaluated by immunohistochemistry (IHC) on primary tumors. Eight patients 
(42%) displayed radiometabolic uptake of any grade intensity with focal and limited distribution. 
Two patients (11%) displayed strong uptake in multiple lesions and were treated with PRRT. Both 
obtained an overall disease control lasting 4 and 12 months, respectively. 
Conclusions. ACC can express SSTRs as detected by IHC and 68Ga-DOTATOC PET. SSTRs-based PRRT 
may represent a potential treatment opportunity for a minority of advanced ACC patients. This 
treatment modality deserves further investigation. 
 
Précis 
More than 50% of advanced ACC patients displays detectable levels of somatostatin receptors by 
means of 68Ga DOTATOC-PET/CT, but only a minority of them are eligible to Peptide Receptor 
Radionuclide Therapy. 
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Introduction 
Patients with metastatic adrenocortical carcinoma (ACC) generally display poor prognosis (1,2) and 
limited therapeutic options are available when disease is progressing after first line chemotherapy 
and mitotane (3).  
Somatostatin (SMS) in endocrine cells has both regulatory functions on endocrine and esocrine 
secretory activities and anti-proliferative properties. SMS analogues represent a standard therapy 
in the management of neuroendocrine tumors (NET) (4). Currently available SMS analogues 
(SSAs), octreotide and lanreotide, bind to 2 of the 5 classes of SMS receptors (SSTRs), described in 
neuroendocrine cells (SSTRs 2 and 5). These SSAs are the radiolabeled peptides for PET imaging 
and Peptide Receptor Radionuclide Therapy (PRRT) (5).  
Few studies investigated SSTRs expression in ACC and none explored the therapeutic role of SSTRs 
in ACC patients (6-8). 
In this study, we evaluated SSTRs expression and reported the results of 90Y/177Lu -DOTATOC PRRT 
in advanced ACC patients. 
 
Methods 
68Ga-DOTATOC-PET/CT was performed in 19 patients with metastatic ACC from two reference 
centers for ACC in Italy. Patients had been previously treated with surgery, mitotane and 
chemotherapy. Fifteen patients underwent 18F-FDG-PET/CT (FDG-PET) that was positive in all of 
them. 
Uptake of 68Ga-DOTATOC in metastatic sites was scored in terms of standard uptake value (SUV) 
intensity (weak/strong, being “strong” similar or superior to liver uptake) and anatomical uptake 
distribution (focal/multiple-diffuse). Tissue expression of SSTRs 2A and 5 was also evaluated by 
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 5 
immunohistochemistry (IHC) on specimens from primary tumors in 14/19 (74%) patients. Detailed 
IHC methods and scoring system have been published elsewhere (9).  
 
Results and case description 
Baseline characteristics of the 19 patients are given in Table 1. SSTR2A and SSTR5 
immunoreactivity with 3+ scores were detected in 2/14 (14%) of patients (Figure 1D-E). Tissue 
expression of SSTR2A correlated with 68Ga-DOTATOC imaging patterns by a Fisher’s test (p=0.011). 
68Ga-DOTATOC uptake of any grade intensity was observed in metastatic lesions of ten ACC 
patients (53%). However, only two patients displayed a clinically significant and strong uptake with 
a diffuse/multiple pattern. Both patients were offered the 90Y- and 177Lu-DOTATOC PRRT, 
according to the DOTATER1_26_15 prospective study approved by the Ethical Committee at the 
Reggio Emilia Hospital in Italy (EudraCT: 2015-005546-63) and signed an informed consent.  
Case 1. In 2002, a 30 yr-old female patient underwent left adrenalectomy and lung 
metastasectomy for a non-secretory, low-grade (Ki-67 10%) ACC. Surgery was radical (R0) and the 
patient started adjuvant mitotane. After 5 years, the disease relapsed in lungs and mediastinal 
lymphnodes. Because of oligometastatic, slowly proliferating disease, mitotane was continued 
until November 2011 and then discontinued after 4 years of tretament. In June 2013, a CT 
revealed one large (> 5 cm) liver metastasis and a left paravertebral lesion. The patient refused 
polychemotherapy and was treated with percutaneous radiofrequency ablation. In November 
2014, new lung and mediastinal metastases were detected. A 68Ga-DOTATOC-PET/CT revealed 
diffuse and strong uptake at multiple metastatic lesions in lung, thoracic wall, mediastinal nodes 
and T11 vertebral body (Figure 1A). In March 2015, the patient was enrolled in the 
DOTATER1_26_15 study and received 4 cycles of PRRT obtaining a partial response, in terms of 
either tumor shrinkage and metabolic down-staging, which lasted 12 months (Figure 1B). In March 
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 6 
2018, the disease further progressed. The patient refused other treatments and died of 
progressing ACC in April 2019. 
Case 2. In November 2005, a 25 yr-old male patient underwent surgical resection of a ACC. 
Surgery was complicated by tumor rupture and peritoneal dissemination of tumor cells. In January 
2006, he underwent salvage surgery for local relapse and entered the follow-up program. In 
November 2012, he experienced a further abdominal recurrence that was surgically resected. 
Histology confirmed low-grade ACC (Ki67 10%). In January 2013, he started post-operative 
mitotane therapy. In May 2014, a CT scan revealed multiple small lung metastases, three 
subcentimetric liver metastases, and a large osteolytic lesion in the left iliac bone. Total body FDG-
PET/CT did not show any uptake except for the osteolytic bone lesion. He started first line 
chemotherapy with cisplatin and etposide plus palliative radiotherapy on the osteolytic lesion (30 
Gy). After 8 chemotherapy cycles, a partial response was observed and the patient was 
maintained on mitotane. On September 2015, the disease progressed again in the lungs and liver. 
A second-line chemotherapy with gemcitabine and capecitabine was introduced but disease 
progression occurred 9 months later and a vast osteolytic lesion involving the left iliac wing and 
sacrum was observed. Because of severe, opioid-unresponsive pain, the bone lesion underwent 
re-irradiation. In December 2017, 68Ga-DOTATOC-PET/CT was performed showing a strong 68Ga 
uptake in the large osteolytic bone lesion (Figure 1C). Other small metastatic lesions in the lung, 
liver and lymph nodes did not show significant uptake. From January to February 2017, the patient 
was treated with PRRT leading to a disease stabilization that lasted 4 months and was associated 
with improvement of bone pain and reduced opioid need. The main side effects were mild back 
pain and WHO G2 lymphopenia. The treatment was interrupted after 2 cycles due to the 
occurrence of a large bone fracture, which forced the patient to bed. He initiated a third line 
chemotherapy with temozolomide, but died in July 2017 for disease progression. 
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Conclusions 
Available data on IHC analysis of SSTRs 1-5 expression in ACC showed that SSTRs have an overall 
low expression with low intensity. Unger et al. found heterogeneous patterns of distribution of 
SSTRs 1-5 with less than 30% of staining intensity (6). Similar results were obtained by Germano et 
al., who reported variable expression in 29% (SSTR2) and 84% (SSTR4) of 58 ACC patients. 
However, treatment of the H295R cell line with the multi-ligand SSA pasireotide, alone or in 
combination with mitotane and/or everolimus, did not have any significant impact on cell growth 
(7). Mariniello et al. demonstrated overexpression of SSTRs 1 and 2 in 13/13 samples of ACC 
patients. Again, they found that pasireotide had antisecretory but not antiproliferative effect on 
the H295R cell line (8). 
In this prospective case series, we demonstrated the presence of SSTR2A and SSTR5 receptors by 
means of 68Ga-DOTATOC PET/CT in more than 50% of patients with advanced ACC. However, 
median SUV level was overall weak and the pattern of 68Ga distribution among neoplastic lesions 
was often focal and heterogeneous. Intratumoral heterogeneity accounted for irregular 
distribution of SSTR 2 and 5 within tumor lesions while maintaining FDG uptake. In only 2 patients 
(11%), the uptake of 68Ga was strong enough to make them eligible to PRRT, which led to overall 
disease control that was long-lasting in one case.  
Parallel IHC analysis of SSTR2A and SSTR5 on primary tumor tissue demonstrated IHC expression in 
43% and 57% of patients, respectively. Of note, SSTR2A tissue expression was scored 3+ in the two 
patients with strong and diffuse uptake in 68Ga-DOTATOC PET/CT, and a correlation between 
tissue immunoreactivity and radiometabolic 68Ga uptake was shown, thus confirming previous 
observations (10). 
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 8 
According to the teranostic principles, 68Ga-DOTA-peptide PET/CT is an imaging modality able to 
select a minority of advanced ACC that could benefit from PRRT. Interestingly, both patients with 
significant 68Ga uptake had low-grade ACC. In light of the paucity of effective treatments for 
advanced ACC, we believe that 90Y/177Lu-DOTATOC PRRT may deserve further investigation. Given 
to its safety profile, PRRT is feasible in heavily pretreated patients and may be tested particularly 
in this setting.  
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Figure 1. SSTR expression by 68Ga-DOTATOC PET imaging and immunohistochemistry.  
A - Patient #9 baseline imaging of lung and pleural metastases.  
B - Patient #9 after 4 treatments with PRRT.  
C – Patient #7 baseline imaging of bone metastasis by 68Ga uptake. White arrows and squares 
indicate metastatic lesions. IHC analysis of  (D) SSTR2A and (E) SSTR5 showing strong 
immunoreactivity (score 3+) in more than 10% of cells (patient #9 [case 1]). 
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Table 1. Baseline characteristics of patients. 
 
Legend of Table 1.  Pt: patient; ENSAT: European Network for the Study of Adrenal Tumors; SUV: standard uptake value; FDG-PET: 18Fluoro-D-
glucose positron emission tomography; PRRT: Peptide Receptor Radionuclide Therapy; age, stage and Ki67 are at diagnosis; NP: not performed; 
NA: not available. 
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Pt, 
sex 
Age ENSAT stage Ki67% SSTR-2A  SSTR-5  Hormone secretion Metastatic   pattern 
N. of previous 
treatments  
68Ga-Dotatoc uptake/ SUV intensity & 
pattern 
FDG-PET uptake 
PRRT/        # 
cycles 
1/F 49 2 50 2+ 0 Cortisol, aldosterone Lung, liver, abdomen 3 Yes/strong/focal Yes No 
2/M 55 3 30 NP NP None Lung 1 Yes/weak/focal Yes No 
3/F 
37 
 
3 >20 1+ 1+ None 
Lung, liver, nodes, 
abdomen, bone 
4 Yes/weak/focal Yes No 
4/F 57 2 25 0 0 Cortisol Lung, nodes 1 No/-/absent Yes No 
5/F 39 2 40 2+ 1+ None 
Lung, liver, abdomen, 
bone 
5 Yes/weak/multiple Yes No 
6/F 61 3 20 0 1+ None 
Lung, liver, nodes, 
abdomen 
2 No/-/absent Yes No 
7/M 25 2 10 3+ 2+ None 
Lung, liver, nodes, 
bone 
2 Yes/strong/diffuse Yes Yes/2 
8/M 63 2 30 1+ 0 None Lung, liver, nodes 3 No/-/absent Yes No 
9/F 55 3 10 3+ 3+ None Lung, nodes, bone 1 Yes/strong/multiple NA Yes/4 
10/F 66 1 8 0 0 None Liver, abdomen 3 No/-/absent Yes No 
11/F 44 2 >20 NP NP None Lung, abdomen 5 Yes/weak/focal Yes No 
12/M  35 3 5 0 0 Aldosterone Lung, liver 1 Yes/weak/focal NA No 
13/F 58 3 10 0 1+ Cortisol 
Lung, liver, nodes, 
abdomen 
3 No/-/absent Yes No 
14/F 49 3 >20 NP NP None Lung, liver 3 No/-/absent NA No 
15/F 52 2 >20 0 2+ None Local, liver, ovary 3 No/-/absent Yes No 
16/F 26 4 >20 0 3+ Cortisol 
Lung, liver, nodes, 
abdomen 
0 Yes/weak/focal Yes No 
17/F 50 4 5 NP NP Cortisol Lung, bone 1 Yes/strong/focal Yes No 
18/F 57 3 10 NP NP Cortisol, testosterone Lung, liver 1 No/-/absent Yes No 
19/M 64 3 15 0 0 Aldosterone 
Lung, liver, 
peritoneum 
2 No/-/absent Yes No 
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Figure 1 
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